Challenge

A major pharma company needed scientific and immunology due diligence support on a novel cyclic peptide, targeting the complement cascade system.

Solution

We reviewed the scientific and mechanistic experiments underpinning the clinical program to understand the risk around a clinical study failing an efficacy endpoint. The research program and resultant data demonstrated a compelling mechanistic rationale to treat the disease and we recommend that our client should proceed from the standpoint of an immunological mechanism of action and scientific merit.

Explore Our Due Diligence Services

Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate.